➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Boehringer Ingelheim
Colorcon
Harvard Business School
Medtronic

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,357,697


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,357,697 protect, and when does it expire?

Patent 8,357,697 protects INGREZZA and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.

Summary for Patent: 8,357,697
Title:Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquin- olin-2-ol compounds and methods relating thereto
Abstract: Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquin- olin-2-ol compounds are disclosed that are inhibitors of the vesicular monoamine transporter 2 (VMAT2). The compounds of this invention have the structure: ##STR00001## wherein R.sub.1 is as defined herein, including stereoisomers and pharmaceutically acceptable salts and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.
Inventor(s): Gano; Kyle W. (San Diego, CA)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:13/237,709
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,357,697

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF TARDIVE DYSKINESIA ⤷  Free Forever Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF TARDIVE DYSKINESIA ⤷  Free Forever Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF TARDIVE DYSKINESIA ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,357,697

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007317242 ⤷  Free Forever Trial
Brazil PI0718247 ⤷  Free Forever Trial
Canada 2668689 ⤷  Free Forever Trial
China 101553487 ⤷  Free Forever Trial
Cyprus 1113838 ⤷  Free Forever Trial
Denmark 2081929 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Baxter
Medtronic
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.